A new therapeutic concept for pancreatic cancer

MoleCure is discovering small-molecule antagonists that block the assembly of the LIF / LIFR / gp130 signaling complex — a trimeric complex that activates the JAK/STAT pathway. Aberrant LIFR signaling drives tumor progression, therapy resistance, and poor survival in pancreatic ductal adenocarcinoma (PDAC), making it a compelling therapeutic target.